由于数据不足, 美国食品和药物管理局要求对亨廷顿病基因疗法进行新的试验. FDA demands new trial for uniQure’s Huntington’s gene therapy due to insufficient data.

美国食品和药物管理局告诉uniQure,其AMT-130基因治疗亨廷顿病的早期数据不足以获得批准,需要对对照组进行新的随机,安慰剂对照试验,并进行假手术. The FDA has told uniQure that early data for its AMT-130 gene therapy for Huntington’s disease are insufficient for approval, requiring a new randomized, placebo-controlled trial with sham surgery for the control group. 该机构指出,尽管治疗具有潜力,但对数据是否可靠以及是否有必要就安全和有效性提供更强有力的证据表示关切。 The agency cited concerns over data robustness and the need for stronger evidence on safety and efficacy, despite the therapy’s potential. 这一决定导致公司库存急剧下降,凸显了监管规范与患者对罕见、致命疾病的紧急需求之间的紧张关系。 The decision, which caused a sharp drop in the company’s stock, highlights the tension between regulatory rigor and urgent patient needs for rare, fatal diseases. 虽然患者倡导者推动加速治疗, 但FDA并未改变立场, 保持严格科学标准的承诺. While patient advocates push for accelerated pathways, the FDA has not signaled a change in its stance, maintaining its commitment to rigorous scientific standards.